Genetics in the Effect of Caffeine on Fat Oxidation

Status Completed

Clinical Trial Summary

Genetic polymorphism on the effect of oral caffeine intake on fat oxidation during exercise has been studied in active and healthy population performing an incremental test on a cycle ergometer with 3-min stages at workloads from 30 to 70% of maximal oxygen uptake (VO2max). Participants performed this test after the ingestion of a) placebo; b) 3 mg/kg of caffeine; c) 6 mg/kg of caffeine. Fat oxidation rate during exercise was measured by indirect calorimetry. The influence of the CYP1A2 c.-163A>C, GSTP c.313A>G and PGC1a polymorphisms was evaluated to determine the effects on fat oxidation during exercise

Clinical Trial Description

Caffeine is a natural stimulant with well-recognized sports performance benefits. Aside its performance-enhancing effect, caffeine has the potential of increasing fat utilization during aerobic exercise at submaximal intensities, lowering-down the contribution of carbohydrate as a fuel. This property of caffeine may provoke a glycogen-sparing effect in the skeletal muscle and liver for exercise situations where carbohydrate availability may be a challenge. Additionally, the capacity of caffeine to enhance fat utilization during exercise could be of interest for improving health outcomes as it may increase the rate of change in body composition in exercise programs. Genetic factors like CYP1A2 c.-163A>C, GSTP c.313A>G and PGC1a c.1444G>A and C>T polymorphisms could be associated with the capacity for fat oxidation during exercise. To date, it is unknown if genetics increases fat oxidation and MFO in the same proportion during morning and evening exercise trials in women. For this reason, the aim of the present study was to evaluate the influence of the tCYP1A2, GSTP and PGC1a polymorphisms on the effect of caffeine on fat oxidation and MFO in active and healthy population. The authors hypothesised that genetics would increase fat oxidation and MFO during exercise and this effect would be of similar magnitude at several caffeine doses. ;

Study Design

Related Conditions & MeSH terms

Caffeine
Fat Burn
Genetic Predisposition
Genetic Predisposition to Disease

Clinical Trial Details

NCT number	NCT05975489
Study type	Interventional
Source	Universidad Francisco de Vitoria
Contact
Status	Completed
Phase	N/A
Start date	October 1, 2020
Completion date	April 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04746794` - Early Detection of GEnetic Risk (EDGE)	N/A
Completed	`NCT03792685` - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention	N/A
Recruiting	`NCT04970056` - Pancreatic Cancer Early Detection Consortium
Terminated	`NCT04119596` - Study of the Genome, Gut Metagenome and Diet of Patients With Incident Parkinson's Disease
Recruiting	`NCT04141462` - EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer	N/A
Completed	`NCT02826330` - Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease
Recruiting	`NCT05929976` - InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
Not yet recruiting	`NCT04620278` - Genetic Investigation of Cancer Predisposition
Active, not recruiting	`NCT02373709` - Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression
Not yet recruiting	`NCT06089421` - Genetic Information Assistant in Telegenetics	N/A
Completed	`NCT03954652` - Whole Genome Trio Sequencing as a Standard Routine Test in Patients With Rare Diseases - "GENOME FIRST APPROACH"	N/A
Completed	`NCT04113239` - Study of the Genome, Gut Metagenome and Lifestyle of Patients With Incident Type 2 Diabetes Mellitus
Enrolling by invitation	`NCT04373525` - Prospective Evaluation on Cognitive Function and Its Associated Genetic Vulnerability in Cannabis Users
Completed	`NCT03362099` - Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING)	Phase 4
Recruiting	`NCT05857670` - Psyco Quality of Life and Procreation BRCA1/2
Active, not recruiting	`NCT04774445` - Effectiveness of MyCancerGene to Optimize Genetic Testing Outcomes	N/A
Not yet recruiting	`NCT06377033` - Using the EHR to Advance Genomic Medicine Across a Diverse Health System	N/A
Recruiting	`NCT05759143` - Enhancing Information Management for Young Adults After Genetic Cancer Risk Testing	N/A
Active, not recruiting	`NCT04920513` - Universal- Versus Guidelines-Directed Genetic Testing for Germline Pathogenic Variants Utilizing a Multi-Gene Panel for Inherited Cancers in Non-Western Society.
Active, not recruiting	`NCT04781205` - Genome Driven Primary Care Clinics - an RCT	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.